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Background: HFPEF, common in elderly, is considered secondary to hypertension (HTN) related “concentric (conc)” LVH (BLVmass and B mass/
volume ratio -MVR) or conc remodeling (CR), and Bdiastolic load, rather than to “eccentric (ecc)” LVH (? MVR). Also, there is association of myocyte 
injury (cTnT), interstitial fibrosis (PIIINP, CITP), and renal dysfunction with HFPEF. However, LVH prevalence has been variable, and previous studies 
have not studied LVH, myocyte injury, fibrosis, and diastolic load (NTproBNP, B LAvol.) in the same cohort.
Methods: In a substudy of the Cardiovascular Health Study, a cohort of 5,888 community-based participants (ppts) ≥ 65 yrs of age, we studied 4 
groups: healthy ppts with no cardiac disease or risk factors, a control group (Risk) without HTN or HFPEF but with risk factors other than HTN, ppts 
with HTN, and ppts with adjudicated HFPEF. We compared group prevalence of conc and ecc LVH, and other abnormalities using CHS partition values 
derived from healthy ppts.
Results: see table. Differences between HFPEF and HTN in bold.
Conclusions: 1. LVH is present in a minority of HFPEF ppts and is more often ecc than conc, c/w volume overload; 2. B MVR (LV hypertrophic 
remodeling) is not > in HFPEF than HTN; 3. myocyte injury, interstitial fibrosis, renal dysfunction, and diastolic load are all > in HFPEF than HTN; 4. 
There is a gradient of abnormality from health to HFPEF. 
Parameter 1Healthy (419) 2Risk (1145) 3HTN (2176) 4HFPEF (150) 1,2 1,3 1,4 2,3 2,4 3,4
LVDD (cm) 4.60±0.03 4.71±0.02 4.76±0.01 4.87±0.05 * * * ns * ns
LVPWT (cm) 0.84±0.01 0.87±0.005 0.91±0.003 0.93±0.01 * * * * * ns
LV mass (g) 130±2.4 143±1.5 155±1.1 165±4.1 * * * * * ns
LV RWT 0.37±0.004 0.38±0.003 0.39±0.002 0.39±0.01 ns * ns * ns ns
LV mass/vol 1.33±0.02 1.38±0.01 1.46±0.01 1.48±0.03 * * * * * ns
LVH prev. 4.9% 12.0% 14.9% 27.6% * * * ns * *
-% ecc 93.3 92.6 81.9 86.2 ns ns ns ns ns ns
-%conc 6.7 7.4 18.1 13.8 ns ns ns ns ns ns
CR 4.6% 6.4% 8.5% 5.7% ns ns ns ns ns ns
LAvol ml/m2 27.9±1.9 34.7±1.1 34.9±0.9 46.2±1.8 * * * ns * *
% LA B 4.3% 18.1% 17.5% 39.8 ns ns * ns * *
pBNP ng/ml 147.3±29.4 245.2±17.4 253.3±13.4 559.4±66.8 ns * * ns * *
%BproBNP 4.8 21.7 26.3 42.3 * * * * * *
cTnT pg/ml 6.4±0.5 7.4±0.3 8.6±0.3 11.5±1.2 ns * * * * ns
%BcTnT 4.8 10.1 14.6 26.8 * * * * * *
eGFR ml/min 79.5±0.8 75.5±0.5 72.9±0.4 64.3±1.8 * * * * * *
ICTP ug/l 4.3±0.4 4.4±0.3 4.7±0.3 7.5±0.4 ns ns * ns * *
%B ICTP 4.7 5.2 7.2 23.3 ns ns * ns * *
PIIINP ug/ml 3.4±1.1 3.5±0.71 4.2±0.77 11.6±0.92.0 ns ns * ns * *
%BPIIINP 4.7 6.3 7.2 22.4 ns ns * ns * *
All parameter trend p <0.001 ANOVA across the 4 strata. * significant pairwise differences, Bonferroni adjusted.
